• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDIVATORS INC. ADVANTAGE PLUS; AUTOMATED ENDOSCOPE REPROCESSOR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDIVATORS INC. ADVANTAGE PLUS; AUTOMATED ENDOSCOPE REPROCESSOR Back to Search Results
Device Problem No Apparent Adverse Event (3189)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 01/03/2020
Event Type  Injury  
Manufacturer Narrative
Medivators field service engineer (fse) was onsite at a facility investigating a reported issue with their advantage plus automated endoscope reprocessor (aer).It was observed the facility was using avantik ultraclear xylene substitute solution in the alcohol bottle in the unit.Avantik is not validated for use in the aer.There is potential residual being left in the aer and in the endoscopes being used in patient procedures.Medivators fse reported that all three of their facilities aers had avantik solution in the alcohol bottle.The fse observed that most rubber components within the aer were damaged.Upon further examination, the fse found multiple other components showing signs of deterioration.The facility was advised to stop using the aers and endoscopes as there was too much damage and unsafe for use.It was reported that at least fourteen cycles had been run with this solution.It has not been confirmed if those endoscopes were used in patient procedures.The advantage plus aer user manual states the solution in the alcohol bottle should be 70% isopropyl alcohol.After close review of avantik ultraclear xylene substitute safety data sheet, this product does not meet that specification.The facility has replaced all three units since medivators fse's initial visit.The facility consulted with their olympus representative and were advised to reprocess the endoscopes once more before continued use.There have been no reports of patient harm.This complaint will continue being monitored in the medivators complaint handling system.
 
Event Description
Medivators field service engineer (fse) was onsite at a facility investigating a reported issue with their advantage plus automated endoscope reprocessor (aer).It was observed the facility was using avantik ultraclear xylene substitute solution in the alcohol bottle in the unit.Avantik is not validated for use in the aer.There is potential residual being left in the aer and in the endoscopes being used in patient procedures.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ADVANTAGE PLUS
Type of Device
AUTOMATED ENDOSCOPE REPROCESSOR
Manufacturer (Section D)
MEDIVATORS INC.
14605 28th ave n
plymouth MN 55447
Manufacturer (Section G)
MEDIVATORS INC.
14605 28th ave n
plymouth MN 55447
Manufacturer Contact
lauren johnson
14605 28th ave n
plymouth, MN 55447
MDR Report Key9627170
MDR Text Key176252753
Report Number2150060-2020-00003
Device Sequence Number1
Product Code FEB
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K102996
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,user f
Reporter Occupation Administrator/Supervisor
Remedial Action Replace
Type of Report Initial
Report Date 01/24/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received01/24/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator No Information
Was Device Available for Evaluation? Yes
Date Manufacturer Received01/08/2020
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured09/18/2019
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage N
Patient Sequence Number1
Treatment
AVANTIK ULTRACLEAR XYLENE SUBSTITUTE
Patient Outcome(s) Other;
-
-